Incomplete surgical resection of cancer tissues is a critical problem in the care for cancer patients, leading to devastating consequences such as recurrence, increased treatment costs, and post-operative complications. Current methods for intraoperative tissue identification and surgical margin evaluation are unreliable), time consuming, and require expert on-call pathologists for interpretation. Additionally, no current methods enable label-free real-time margin evaluation and cancer detection in vivo to guide surgical decision making. MS Pen Technologies is developing the ultimate tissue sensing system (Ultiss MD), a platform for tissue sensing and surgical guidance that combines the sim...

Read More

Incomplete surgical resection of cancer tissues is a critical problem in the care for cancer patients, leading to devastating consequences such as recurrence, increased treatment costs, and post-operative complications. Current methods for intraoperative tissue identification and surgical margin evaluation are unreliable), time consuming, and require expert on-call pathologists for interpretation. Additionally, no current methods enable label-free real-time margin evaluation and cancer detection in vivo to guide surgical decision making. MS Pen Technologies is developing the ultimate tissue sensing system (Ultiss MD), a platform for tissue sensing and surgical guidance that combines the simplicity of our proprietary MasSpec Pen, the performance of mass spectrometry, and the power of AI/ML software. Ultiss exploits the fundamentals of tumor biology to detect cancer on a molecular level in vivo to guide surgical decision making in real-time. Our initial focus is lung cancer, a deadly disease that claims more lives in the US and TX than breast, colon and prostate cancer combined, and where curative resection is highly dependent on intraoperative decision making. With funding, we will develop the Ultiss MD, refine our data analytics and AI/ML algorithms, and perform pilot studies in lung cancer surgery. The outcome of these efforts will provide a path towards regulatory approval of the Ultiss MD and establish a new era for molecular-based precision surgery.

Read Less